ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Language English Country Ireland Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
33712263
DOI
10.1016/j.radonc.2020.11.018
PII: S0167-8140(20)31188-9
Knihovny.cz E-resources
- Keywords
- Endometrial carcinoma, Guidelines, Management, Molecular markers, Staging,
- MeSH
- Consensus MeSH
- Humans MeSH
- Endometrial Neoplasms * radiotherapy MeSH
- Radiation Oncology * MeSH
- Risk Factors MeSH
- Guidelines as Topic * MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Europe MeSH
A European consensus conference on endometrial carcinoma was held in 2014 to produce multidisciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since 2014, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and the European Society of Pathology (ESP) jointly decided to update these evidence-based guidelines and to cover new topics in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide. ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of endometrial carcinoma (27 experts across Europe). To ensure that the guidelines are evidence-based, the literature published since 2014, identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 191 independent international practitioners in cancer care delivery and patient representatives. The guidelines comprehensively cover endometrial carcinoma staging, definition of prognostic risk groups integrating molecular markers, pre- and intra-operative work-up, fertility preservation, management for early, advanced, metastatic, and recurrent disease and palliative treatment. Principles of radiotherapy and pathological evaluation are also defined.
Clinical Research Unit Institut Bergonie Bordeaux France
Department of Gynaecologic Oncology Imperial College London Faculty of Medicine UK
Department of Gynaecology Royal Marsden Hospital London UK
Department of Gynecology and Obstetrics TU Dresden Medizinische Fakultat Carl Gustav Carus Germany
Department of Medical Oncology Amsterdam University Medical Centres Noord Holland Netherlands
Department of Medical Oncology Clinica Universidad de Navarra Madrid Spain
Department of Medical Oncology St James Hospital Dublin Ireland
Department of Obstetrics and Gynecology Innsbruck Medical University Austria
Department of Oncology Rigshospitalet Copenhagen University Hospital Denmark
Department of Pathology Leids Universitair Medisch Centrum Leiden Netherlands
Department of Radiation Oncology Institut Gustave Roussy Villejuif France
Department of Radiation Oncology Leiden University Medical Center Leiden Netherlands
Department of Radiation Oncology Medical Faculty of the University of Cologne Germany
Department of Radiotherapy Erasmus MC Cancer Institute Rotterdam Netherlands
Department of Surgery Institut Gustave Roussy Villejuif France
Division of Gynecologic Oncology Fondazione Policlinico Universitario A Gemelli IRCCS Rome Italy
Histopathology and Molecular Diagnostics Azienda Ospedaliero Universitaria Careggi Florence Italy
References provided by Crossref.org
New FIGO 2023 Staging System of Endometrial Cancer: An Updated Review on a Current Hot Topic
